Loading
A phase 2 trial of SC-101 run by Tianjin ConjuStar Biologics Co., Ltd., now recruiting.
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers is a phase 2 interventional study registered as NCT07080619 by Tianjin ConjuStar Biologics Co., Ltd., with 120 participants planned, started 2025-08-26. Conditions recorded: TNBC - Triple-Negative Breast Cancer and HR+ Breast Cancer. Interventions recorded: SC-101.
Shares SC-101, ConjuStar Biologics and the tag pipeline.
Shares ConjuStar Biologics and the tag pipeline.
Shares ConjuStar Biologics and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/